These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38144608)

  • 1. Use of secukinumab in erythrodermic psoriasis: A single center experience.
    Bhatnagar A; Singh GK; Deshpande SK; Mitra B; Mitra D; Agrawal V; Reddy S; Patil C; Sandhu S
    Med J Armed Forces India; 2023 Dec; 79(Suppl 1):S6-S12. PubMed ID: 38144608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab.
    Galluzzo M; D'Adamio S; Campione E; Mazzilli S; Bianchi L; Talamonti M
    J Dermatolog Treat; 2018 Sep; ():1-11. PubMed ID: 30256706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab.
    Pizzatti L; Mugheddu C; Sanna S; Atzori L; Rongioletti F
    Dermatol Ther; 2020 May; 33(3):e13348. PubMed ID: 32239791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrodermic Psoriasis Treated with Apremilast.
    Arcilla J; Joe D; Kim J; Kim Y; Truong VN; Jaipaul N
    Dermatol Reports; 2016 Jun; 8(1):6599. PubMed ID: 27942369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
    Liu LC; Jin XH; Sun C; Xia JX
    Dermatol Ther; 2021 Mar; 34(2):e14825. PubMed ID: 33527631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy.
    Ellis J; Lew J; Brahmbhatt S; Gordon S; Denunzio T
    Case Rep Med; 2019; 2019():8165808. PubMed ID: 31031815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study.
    Damiani G; Pacifico A; Russo F; Pigatto PDM; Bragazzi NL; Bonifati C; Morrone A; Watad A; Adawi M
    J Clin Med; 2019 May; 8(6):. PubMed ID: 31159169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.
    Lu J; Tang S; Yu N; Yi X; Li Y
    J Int Med Res; 2020 Nov; 48(11):300060520969494. PubMed ID: 33161790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab in Erythrodermic Psoriasis: Real World Experience of 6 Patients Successfully Treated by Injecting at Unconventional Sites.
    Panda M; Raj C; Panda AK; Debata I
    Indian J Dermatol; 2021; 66(6):677-680. PubMed ID: 35283534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature.
    Ali AK; Torosian A; Porter C; Bloomfeld RS; Feldman SR
    Dermatol Ther; 2021 Nov; 34(6):e15151. PubMed ID: 34609037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report.
    Lu X; Wang W
    Clin Cosmet Investig Dermatol; 2023; 16():1977-1981. PubMed ID: 37539023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical analysis of 84 cases of erythrodermic psoriasis and 121 cases of other types of erythroderma from 2010-2015.
    Zhang P; Chen HX; Xing JJ; Jin Z; Hu F; Li TL; Zhou XY
    J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):563-567. PubMed ID: 28786071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.
    Blauvelt A; Pariser DM; Tyring S; Bagel J; Alexis AF; Soung J; Armstrong AW; Muscianisi E; Kianifard F; Steadman J; Sarkar RP; Garcet S; Krueger JG
    J Dermatol Sci; 2023 Jan; 109(1):12-21. PubMed ID: 36690571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of TNF-α inhibition
    Elliott A; Wright G; Pendleton A; Rooney M
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231179524. PubMed ID: 38024204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrodermic Psoriasis in a Patient with Plaque Psoriasis Who Presented with Symptoms of Niacin Deficiency: A Special Case Report.
    Wu H; Shen Y; Zhang L; Yang M; Ren Y; Mao F; Wu Z
    Clin Cosmet Investig Dermatol; 2022; 15():2097-2100. PubMed ID: 36213316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.